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B r i e f c o m m u n i c at i o n s Activation of m opioid receptors by morphine in the brainstem and spinal cord produces analgesia 1 , but the relevant post-receptor mechanisms are unknown. In the brainstem, opioid-induced stimulation of descending circuits from the ventrolateral periaqueductal gray (PAG) and rostral ventromedial medulla (RVM) produces powerful inhibition of spinal nociceptive transmission 1 . In the PAG, m opioid receptors activate these circuits by increasing a presynaptic, voltagedependent potassium conductance that inhibits GABA release 2 . Biochemical 3 and electrophysiological 2 studies have suggested that phospholipase A 2 (PLA 2 ) and its product, arachidonic acid, are important for such analgesic signaling. We evaluated the arachidonate epoxygenase pathway (Supplementary Fig. 1) , which uses P450s to produce up to four distinct epoxyeicosatrienoic acid isomers (EETs) 4 , as a brain m opioid analgesic transduction mechanism.
To circumvent the complexities of over 120 distinct mouse P450 genes (http://drnelson.utmem.edu/CytochromeP450.html) and the overlapping functions of multiple P450s, we generated a brain neuron-specific transgenic mouse (brain-Cpr null, null). In these mice, the loxP-flanked Cpr gene (encoding cytochrome P450 reductase (CPR), the enzyme required for all microsomal P450 activity, also known as Por) was targeted for deletion in Cre-expressing CNS neurons (via Camk2a-cre, under control of the Camk2a promoter, see Supplementary Methods). Consistent with the pattern of Camk2a-cre expression 5 , immunohistochemistry confirmed the loss of neuronal CPR in the cerebral cortex ( Fig. 1) , hypothalamus ( Supplementary  Fig. 2 ) and hippocampus ( Supplementary Figs. 2 and 3) of null, but not control, mice. However, Camk2a-cre expression is not limited to the forebrain 5 . Careful inspection of the brainstem of null mice revealed a discrete population of neurons in the ventrolateral PAG that were not labeled with antibody to CPR; CPR was abundantly expressed in same-sized neurons from the same brain area of control mice ( Fig. 1) . As compared with controls, null mouse brains had reduced levels of CPR protein expression ( Supplementary Fig. 4 ), CPR activity (Supplementary Fig. 4 ) and P450 activity ( Supplementary  Table 1 ). CPR protein levels in brainstem homogenates were not different between genotypes ( Supplementary Fig. 4) , which is consistent with the highly localized loss of CPR that we observed in the PAG of Opioids activate brain analgesic circuits through cytochrome P450/epoxygenase signaling To assess the importance of brain cytochrome P450 (P450) activity in  opioid analgesic action, we generated a mutant mouse with brain neuron-specific reductions in P450 activity; these mice showed highly attenuated morphine antinociception compared with controls. Pharmacological inhibition of brain P450 arachidonate epoxygenases also blocked morphine antinociception in mice and rats. Our findings indicate that a neuronal P450 epoxygenase mediates the pain-relieving properties of morphine. 1 Center for Neuropharmacology and Neuroscience, Albany Medical College, Albany, New York, USA. 2 8 These authors contributed equally to this work. 9 These authors jointly directed the study. Correspondence should be addressed to L. B r i e f c o m m u n i c at i o n s null mice ( Fig. 1) . Null mice were healthy, showed normal behavior and had normal brain morphology ( Supplementary Fig. 5 ). All animal experiments were approved by the Institutional Animal Care and Use Committees of either Albany Medical College or the Wadsworth Center.
We used null mice to examine the role of neuronal P450s in morphine antinociception. Systemically administered morphine increased thermal nociceptive latencies in control mice; this effect was abolished in null mice 40 and 60 min after drug ( Fig. 2a) . ANOVA (between groups #1, drug; between groups #2, genotype; within [repeated measures], time) found main effects of genotype (F 1,15 = 7.4, P < 0.02), drug (F 1,15 = 17.5, P < 0.01) and time (F 3,45 = 10.4, P < 0.01), and significant drug by genotype (F 1,15 = 7.4, P < 0.02), time by genotype (F 3,45 = 3.8, P < 0.02), time by drug (F 3,45 = 6.0, P < 0.01) and threeway (F 3,45 = 3.8, P < 0.02) interactions. Further studies documented that this deficit occurred in null mice of both sexes and after varying doses of morphine ( Fig. 2b) . ANOVA (between groups #1, dose; between groups #2, genotype) found significant main effects of dose (F 2,39 = 15.2, P < 0.01) and genotype (F 1,39 = 16.2, P < 0.01) and a significant two-way interaction (F 2,39 = 4.0, P < 0.05). Null mice also showed deficient antinociceptive responses to morphine assessed in a mechanical nociceptive test ( Fig. 2c) . ANOVA (between groups #1, drug; between groups #2, genotype; within [repeated measures], time) found significant main effects of drug (F 1,15 = 26.8, P < 0.01), genotype (F 1,15 = 8.8, P < 0.01) and time (F 1,15 = 17.0, P < 0.01), and significant genotype by drug (F 1,15 = 7.0, P < 0.02), time by drug (F 1,15 = 14.2, P < 0.01), time by genotype (F 1,15 = 7.0, P < 0.02) and three-way interactions (F 1,15 = 6.5, P < 0.05). Baseline (pre-drug) nociceptive latencies and those following saline treatment did not differ between genotypes ( Fig. 2a-c) . Baseline latencies were also not different between genotypes following exposure to milder thermal (48 °C versus 55 °C) or mechanical (400 g versus 600 g) stimuli (data not shown). Thus, null mice responded normally to painful stimuli, but were highly resistant to the antinociceptive properties of morphine. Furthermore, the lack of genotype differences in either opioid receptor properties or brain morphine levels (Supplementary Fig. 6 ) indicates that these variables do not explain the defective morphine antinociception in null mice. The absence of genotype differences in brain morphine levels is consistent with the known metabolism of morphine by glucuronidation, a non-P450 pathway. It was not necessary to measure brain levels of the active metabolite morphine-6-glucuronide, as this metabolite is not formed in mice 6 .
We performed complementary pharmacological experiments in control subjects. Treatment of control mice with the P450 blocker MW06-25 ( Supplementary Fig. 7 ) attenuated morphine antinociception ( Fig. 3a) , consistent with our findings in null mice. ANOVA (between groups, drug; within groups [repeated measures], time) revealed significant main effects of drug (F 5,84 = 6.7, P < 0.01) and time (F 4,84 = 11.0, P < 0.01) and a significant drug by time interaction (F 20,84 = 2.9, P < 0.01). MW06-25 lacked activity on other (b) Rats were tested for tail flick nociceptive responses exactly as in a, except that icv morphine (MOR, 20 mg) was administered immediately following post-icv testing. When tested in the absence of morphine, none of these inhibitor treatments modified nociceptive latencies (data not shown). Significant differences are labeled as in a. Results were nearly identical on the hot plate test (data not shown). Table 2) , confirming a P450 target for this drug (Supplementary Fig. 8 ). Note that systemic morphine antinociception was not completely abolished in null mice (Fig. 2b) or by P450 inhibitors in control subjects (Fig. 3a) . Explanations for this residual morphine effect might include incomplete attenuation of supraspinal P450 activity, spinal sites for opioid action or alternative non-epoxygenase opioid transduction mechanisms 2 . In further studies in rats, we found that CNS administration of several P450 inhibitors (Supplementary Fig. 8 ) also blocked the antinociceptive effects of centrally administered morphine (Fig. 3b) , confirming a supraspinal localization (for example, PAG and RVM) for the opioid-P450 interaction. ANOVA (between groups, drug; within groups [repeated measures], time) revealed a significant main effect of time (F 3,81 = 16.3, P < 0.01) and a significant drug by time interaction (F 12,81 = 2.3, P < 0.02). The CPR-deficient ventrolateral PAG neurons that we identified in null mice (Fig. 1) may normally contain the analgesia-relevant P450s, but this requires further study. P450s can metabolize arachidonic acid by hydroxylation as well as by epoxidation. However, we found that treatment with MS-PPOH (which inhibits the latter, but not the former, reaction 7 ) blocked morphine antinociception in both control mice ( Fig. 3a) and rats (Fig. 3b) , strongly supporting a P450 epoxygenase mechanism in morphine action. m opioid receptors couple with G proteins to stimulate many intracellular pathways 8 , but epoxygenase-mediated m signaling has not been previously proposed. Consistent with this model ( Supplementary  Fig. 1) , m activation can increase arachidonate synthesis through stimulation of PLA 2 (refs. 2,3) . In the brain, this could occur via sequential activation of phospholipase Cγ, inositol-1,4,5-triphosphate receptors 9,10 and calcium-dependent PLA 2 . Alternatively, arachidonate synthesis could be increased via diacylglycerol metabolism. Other consistent findings include the potentiation of m agonist action by cyclooxygenase inhibitors 11 and the enhanced morphine antinociception in 12-lipoxygenase (12-LOX) knockout mice 12 . Both observations could be explained via shunting of arachidonate from the cyclooxygenase or 12-LOX pathways to the epoxygenase pathway. Also supporting an epoxygenase model is the recently described antinociceptive activity of the epoxygenase product 14,15-EET following PAG administration 13 . Although EETs have numerous biological activities 4 , the mechanisms by which this or other EET isomers might activate analgesic circuits remain unknown. EETs may act on EET receptors or directly on ion channels 4 . However, EET metabolites are numerous 4 and could also be active. A voltage-gated potassium channel may be essential for m agonist action in the PAG 2 , but the effects of EETs on these channels have not yet been determined.
Previously, a P450 inhibitor was reported to block m opioid action in vitro 2 . Because P450 enzymes were thought to be important in the 12-LOX metabolic pathway, this and other findings led the authors to propose a m opioid-12-LOX mechanism for analgesic signaling 2, 11 . Although P450 activity may not be required for the synthesis of 12-LOX metabolites 14 , both 12-LOX and P450 epoxygenase enzymes could be important in m opioid action. To further address this, additional studies are needed to identify the arachidonate metabolite(s) that are released by morphine and are required for its analgesic actions.
Our results suggest an essential role for brain P450 epoxygenases in the pain-relieving properties of m opioids, but additional studies are needed to fully understand the implications of these findings. For example, other brain-acting analgesics (for example, delta and kappa opioids, cannabinoids 15 ) may require P450 activity. In the case of morphine, it is not known whether P450s have a specific role in m-activated analgesic circuits or a more general role in opioid receptor transduction mechanisms. For example, P450s may not be required for morphine's therapy-limiting side effects, such as respiratory depression, tolerance or rewarding effects leading to addiction. Identification of the analgesia-relevant brain P450s could lead to new treatments for pain.
Note: Supplementary information is available on the Nature Neuroscience website.
